{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:09:35Z","timestamp":1787504975170,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>While the oncogenic potential of HPV has been well-established in other disease sites (e.g. cervix, vulva, anus), it is increasingly evident that a significant proportion of oropharyngeal cancer cases are related to the virus. Although considerable progress has been made in the understanding of this disease with respect to its underlying biology and clinical behavior, numerous questions persist. From a therapeutic standpoint, HPV-positive oropharyngeal cancer has been shown to be more radiosensitive than HPV-negative disease. However, how HPV mediates this radiosensitivity is relatively uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Given that it has been firmly established that patients with HPV-positive oropharyngeal cancer have a significantly improved prognosis as a result of their exquisite response to radiation and can be treated with less-than-standard doses, logical questions pertain to how HPV confers this benefit to infected patients. Although the exact reason for the improved radiosensitivity of HPV-positive oropharyngeal carcinoma is unclear, multiple theories have been proposed. Indeed, it is likely that no single explanation exists for the increased radiosensitivity, and instead, HPV likely exerts its influence through a cascade of activated pathways at both the cellular level and tumor microenvironment. As will be discussed in this review, the proposed mechanisms for HPV-induced radiation response have generally centered on the disruption of such cellular pathways as DNA repair, cell cycle checkpoints, metabolic-induced stress, immunology, and cancer stem cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Given that HPV-positive oropharyngeal cancer is increasingly recognized as a public health problem, the search to better understand its unique biological radiosensitivity has important societal and treatment-related implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-025-01666-2","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:27:45Z","timestamp":1744352865000},"page":"634-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["HPV-Mediated Radiosensitivity in Oropharyngeal Squamous Cell Carcinoma:\u00a0Molecular Mechanisms and Cellular\u00a0Pathways"],"prefix":"10.1007","volume":"27","author":[{"given":"Allen M.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"1666_CR1","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1200\/JCO.22.02625","volume":"41","author":"AK Chaturvedi","year":"2023","unstructured":"Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Onol. 2023;41:3081\u20138.","journal-title":"J Clin Onol"},{"key":"1666_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335.","journal-title":"N Engl J Med"},{"key":"1666_CR3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2009.03.004","volume":"74","author":"AK Gupta","year":"2009","unstructured":"Gupta AK, Lee JH, Wilke WW, et al. Radiation response in two HPV-infected head and neck cancer cell lines in comparison to non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys. 2009;74:928\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1666_CR4","volume-title":"American Joint Committee on Cancer staging manual","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, et al editors. American Joint Committee on Cancer staging manual. 8th ed. New York: Springer; 2017.","edition":"8"},{"key":"1666_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/hed.24974","volume":"40","author":"JD Cramer","year":"2018","unstructured":"Cramer JD, Hicks KE, Rademaker AW, et al. Validation of the eighth edition american joint committee on cancer staging system for human papillomavirus-associated oropharyngeal cancer. Head Neck. 2018;40:457\u201366.","journal-title":"Head Neck"},{"key":"1666_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","volume":"18","author":"AM Chen","year":"2017","unstructured":"Chen AM, Felix C, Wang PC, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017;18:803\u201311.","journal-title":"Lancet Oncol"},{"key":"1666_CR7","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1200\/JCO.19.01007","volume":"37","author":"BS Chera","year":"2019","unstructured":"Chera BS, Amdur RJ, Tepper J, et al. Phase 2 trial of de-intensified chemoradiation therapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2019;37:2661\u20139.","journal-title":"J Clin Oncol"},{"key":"1666_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.20.03128","volume":"39","author":"SS Yom","year":"2021","unstructured":"Yom SS, Torres-Saavedra P, Caudell JJ, et al. Reduced dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG 002). J Clin Oncol. 2021;39:956\u201365.","journal-title":"J Clin Oncol"},{"key":"1666_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0360-3016(96)00448-8","volume":"37","author":"TL Deweese","year":"1997","unstructured":"Deweese TL, Walsh JC, Dillehayetal LE, et al. Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose- rate radiation\u201d. Int J Radiat Oncol Biol Phys. 1997;37:145\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1666_CR10","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1054\/bjoc.2000.1114","volume":"82","author":"MC Kamradt","year":"2000","unstructured":"Kamradt MC, Mohideen N, Krueger E, et al. Inhibition of radiation-induced apoptosis lay dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6\/E7. The British Journal of Cancer. 2000;82:1709\u201316.","journal-title":"The British Journal of Cancer"},{"key":"1666_CR11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1096\/fj.00-0728fje","volume":"15","author":"L Hampson","year":"2001","unstructured":"Hampson L, El Hady ES, Moore JV, et al. The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. FASEB J. 2001;15:1445\u20137.","journal-title":"FASEB J"},{"key":"1666_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","volume":"24","author":"H Mehanna","year":"2023","unstructured":"Mehanna H, Taberna M, von Buchwald C, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 2023;24:239\u201351.","journal-title":"Lancet Oncol"},{"key":"1666_CR13","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1158\/0008-5472.CAN-21-2101","volume":"82","author":"DP Molkentine","year":"2022","unstructured":"Molkentine DP, Molkentine JM, Bridges KA, et al. p16 represses DNA damage repair via a novel ubiquitin-dependent signaling cascade. Cancer Res. 2022;82:916\u201328.","journal-title":"Cancer Res"},{"key":"1666_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.micinf.2017.06.001","volume":"19","author":"F Faraji","year":"2017","unstructured":"Faraji F, Zaidi M, Fahkry C, et al. Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer. Microbes Infect. 2017;19:464\u201375.","journal-title":"Microbes Infect"},{"key":"1666_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.18632\/oncotarget.27535","volume":"11","author":"M Zhang","year":"2020","unstructured":"Zhang M, Hong AM. The human papillomavirus confers radiosensitivity in oropharyngeal cancer cells by enhancing DNA double strand break. Oncotarget. 2020;11:1417\u201326.","journal-title":"Oncotarget"},{"key":"1666_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.virol.2020.05.003","volume":"547","author":"T Kono","year":"2020","unstructured":"Kono T, Hoover P, Poropatich K, et al. Activation of DNA damage repair factors in HPV positive oropharyngeal cancers. Virology. 2020;547:27\u201334.","journal-title":"Virology"},{"key":"1666_CR17","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.3390\/cancers13153717","volume":"13","author":"M Bamps","year":"2021","unstructured":"Bamps M, Dok R, Nuyts S. The DNA damage response is differentially involved in HPV-positive and HPV-negative radioresistant head and neck squamous cell carcinoma. Cancers. 2021;13:3717.","journal-title":"Cancers"},{"key":"1666_CR18","doi-asserted-by":"publisher","first-page":"765968","DOI":"10.3389\/fonc.2022.765968","volume":"12","author":"S Kocher","year":"2022","unstructured":"Kocher S, Zech HB, Gatzemeier F, et al. A lack of effectiveness in the ATM-orchestrated DNA damage response contributes to the DNA repair deficit of HPV-positive head and neck cancer cells. Front Oncol. 2022;12:765968.","journal-title":"Front Oncol"},{"key":"1666_CR19","doi-asserted-by":"publisher","first-page":"21573","DOI":"10.1073\/pnas.1906120116","volume":"116","author":"JE Leeman","year":"2019","unstructured":"Leeman JE, Li Y, Bell A, et al. Human papillomavirus 16 promotes microhomology-mediated end-joining. PNAS. 2019;116:21573\u20139.","journal-title":"PNAS"},{"key":"1666_CR20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-11-2058","volume":"18","author":"E Gubanova","year":"2012","unstructured":"Gubanova E, Brown B, Ivanov SV, et al. Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin Cancer Res. 2012;18:1257\u201367.","journal-title":"Clin Cancer Res"},{"key":"1666_CR21","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1158\/0008-5472.CAN-13-2479","volume":"74","author":"R Dok","year":"2014","unstructured":"Dok R, Kalev P, Limergen EJ, et al. p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Cancer Res. 2014;74:1739\u201351.","journal-title":"Cancer Res"},{"key":"1666_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.7150\/ijbs.40880","volume":"16","author":"H Wang","year":"2020","unstructured":"Wang H, Wang B, Wei J, et al. Molecular mechanisms underlying increased radiosensitivity in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Biol Sci. 2020;16:1035\u201343.","journal-title":"Int J Biol Sci"},{"key":"1666_CR23","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ijrobp.2010.06.028","volume":"79","author":"EP Pang","year":"2011","unstructured":"Pang EP, Delic NC, Hong A, et al. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6*I. Int J Oncol Biol Phys. 2011;79:860\u20135.","journal-title":"Int J Oncol Biol Phys"},{"key":"1666_CR24","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1158\/0008-5472.CAN-13-0587","volume":"73","author":"RJ Kimple","year":"2013","unstructured":"Kimple RJ, Smith MA, Blitzer GC, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 2013;73:4791\u2013800.","journal-title":"Cancer Res"},{"key":"1666_CR25","doi-asserted-by":"publisher","first-page":"89681","DOI":"10.18632\/oncotarget.20813","volume":"8","author":"J Knuth","year":"2017","unstructured":"Knuth J, Sharma SJ, Wurdemann N, et al. Hypoxia-inducible factor-1\u03b1 activation in HPV-positive head and neck squamous cell carcinoma cell lines. Oncotarget. 2017;8:89681\u201391.","journal-title":"Oncotarget"},{"key":"1666_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(05)70292-8","volume":"6","author":"J Overgaard","year":"2005","unstructured":"Overgaard J, Eriksen JG, Nordsmark M, et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitizer nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomized double-blind placebo-controlled trial. Lancet Oncol. 2005;6:757\u201364.","journal-title":"Lancet Oncol"},{"key":"1666_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.radonc.2011.09.010","volume":"102","author":"K Toustrup","year":"2012","unstructured":"Toustrup K, Sorensen BS, Lassen P, et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol. 2012;102:122\u20139.","journal-title":"Radiother Oncol"},{"key":"1666_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.radonc.2009.10.008","volume":"94","author":"P Lassen","year":"2010","unstructured":"Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol. 2010;94:30\u20135.","journal-title":"Radiother Oncol"},{"key":"1666_CR29","doi-asserted-by":"publisher","first-page":"51530","DOI":"10.18632\/oncotarget.17887","volume":"8","author":"YS Jung","year":"2017","unstructured":"Jung YS, Naiv AJ, Huang W, et al. HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer. Oncotarget. 2017;8:51530\u201341.","journal-title":"Oncotarget"},{"key":"1666_CR30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ijrobp.2020.08.029","volume":"108","author":"YM Mowery","year":"2020","unstructured":"Mowery YM, Vergaslasova I, Rushing CN, et al. Early 18-F-FDG-PET response during radiation therapy for HPV-related oropharyngeal cancer may predict disease recurrence. Int J Radiat Oncol Biol Phys. 2020;108:969\u201376.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1666_CR31","doi-asserted-by":"crossref","unstructured":"Regan SN, Cao Y, Allen SG, et al. 16-FDG-PET-based selective de-escalation of radiotherapy for HPV-related oropharynx cancer: results form a phase II trial. 2024 Multidisciplinary Head and Neck Cancers Symposium. Int J Radiat Oncol Biol Phys. 2024;118:e11.","DOI":"10.1016\/j.ijrobp.2024.01.031"},{"key":"1666_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijrobp.2016.04.027","volume":"96","author":"N Lee","year":"2016","unstructured":"Lee N, Schoder H, Beattie B, et al. Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomarivus-related oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2016;96:9\u201317.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1666_CR33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1200\/JCO.23.01308","volume":"42","author":"NY Lee","year":"2024","unstructured":"Lee NY, Sherman EJ, Schoder H, et al. Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma. J Clin Onol. 2024;42:940\u201350.","journal-title":"J Clin Onol"},{"key":"1666_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3892\/ijo.2013.1953","volume":"43","author":"JE Oh","year":"2013","unstructured":"Oh JE, Kim JO, Shin JY, et al. Molecular genetic characterization of p53 mutated oropharyngeal squamous cell carcinoma cells transformed with human papillomavirus E6 and E7 oncogenes. Int J Oncology. 2013;43:383\u201393.","journal-title":"Int J Oncology"},{"key":"1666_CR35","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/hed.23231","volume":"35","author":"M Broglie","year":"2013","unstructured":"Broglie M, Soltermann A, Rohrbach D, et al. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. Head Neck. 2013;35:1698\u2013706.","journal-title":"Head Neck"},{"key":"1666_CR36","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.radonc.2016.02.009","volume":"118","author":"A Hong","year":"2016","unstructured":"Hong A, Zhang X, Jones D, et al. Relationships between p53 mutation, HPV status, and outcome in oropharyngeal squamous cell carcinoma. Radiother Oncol. 2016;118:342\u20139.","journal-title":"Radiother Oncol"},{"key":"1666_CR37","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/annonc\/mdw426","volume":"27","author":"I Tinhofer","year":"2016","unstructured":"Tinhofer I, Stenzinger A, Eder T, et al. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. Ann Oncol. 2016;27:2262\u20138.","journal-title":"Ann Oncol"},{"key":"1666_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jjco\/hyt223","volume":"44","author":"S Shinohara","year":"2014","unstructured":"Shinohara S, Kikuchi M, Tona R, et al. Prognostic impact of p16 and p53 expression inoropharyngeal squamous cell carcinomas. Jpn J Clin Oncol. 2014;44:232\u201340.","journal-title":"Jpn J Clin Oncol"},{"key":"1666_CR39","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ijrobp.2016.01.005","volume":"94","author":"E Vlashi","year":"2016","unstructured":"Vlashi E, Chen AM, Boyrie S, et al. Radiation-induced dedifferentiation of head and neck cancer cells into cancer stem cells depends on human papillomavirus status. Int J Radiat Oncol Biol Phys. 2016;94:1198\u2013206.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1666_CR40","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2013.11.010","volume":"50","author":"MM Rietbergen","year":"2014","unstructured":"Rietbergen MM, Martens-de Kemp SR, Bloemena E, et al. Cancer stem cell enrichment marker CD98: a prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur J Cancer. 2014;50:765\u201373.","journal-title":"Eur J Cancer"},{"key":"1666_CR41","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archoto.2009.159","volume":"135","author":"WC Spanos","year":"2009","unstructured":"Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009;135:1137\u201346.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"1666_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s11604-021-01231-4","volume":"40","author":"M Someya","year":"2022","unstructured":"Someya M, Fukushima Y, Hasegawa T, et al. Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy. Jpn J Radiol. 2022;40:458\u201365.","journal-title":"Jpn J Radiol"},{"key":"1666_CR43","doi-asserted-by":"publisher","first-page":"e20200389","DOI":"10.1084\/jem.20200389","volume":"217","author":"KH Bhatt","year":"2020","unstructured":"Bhatt KH, Neller MA, Srihari S, et al. Profiling HPV-16\u2013specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. J Exp Med. 2020;217:e20200389.","journal-title":"J Exp Med"},{"key":"1666_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/bjc.2013.639","volume":"110","author":"MJ Ward","year":"2013","unstructured":"Ward MJ, Thirdborough SM, Mellows T, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2013;110:489\u2013500.","journal-title":"Br J Cancer"},{"key":"1666_CR45","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41416-022-01708-7","volume":"126","author":"A Almangush","year":"2022","unstructured":"Almangush A, Jouhi L, Atula T, et al. Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. Br J Cancer. 2022;126:1589\u201394.","journal-title":"Br J Cancer"},{"key":"1666_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/cncr.29100","volume":"121","author":"SH Huang","year":"2015","unstructured":"Huang SH, Waldron JN, Milsevic M, et al. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2015;121:545\u201355.","journal-title":"Cancer"},{"key":"1666_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.oraloncology.2018.11.030","volume":"89","author":"J Meshman","year":"2019","unstructured":"Meshman J, Velez MA, Wang PC, et al. Immunologic mediators of outcome for irradiated oropharyngeal carcinoma based on human papillomavirus status. Oral Oncol. 2019;89:121\u20136.","journal-title":"Oral Oncol"},{"key":"1666_CR48","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/s41598-019-49771-0","volume":"9","author":"J Wang","year":"2019","unstructured":"Wang J, Sun H, Zeng Q, et al. HPV-positive status associated with inflamed immunemicro environment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep. 2019;9:13404.","journal-title":"Sci Rep"},{"key":"1666_CR49","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hed.26036","volume":"42","author":"JJ Patel","year":"2020","unstructured":"Patel JJ, Levy D, Nguyen SA, et al. Impact of PD-L1 expression and human papillomavirus status in anti-PD1\/PDL1 immunotherapy for head and neck squamous cell carcinoma\u2014Systematic review and meta-analysis. Head Neck. 2020;42:774\u201386.","journal-title":"Head Neck"},{"key":"1666_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","volume":"73","author":"C Badoual","year":"2013","unstructured":"Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128\u201338.","journal-title":"Cancer Res"},{"key":"1666_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2019.04.032","volume":"456","author":"X Chen","year":"2019","unstructured":"Chen X, Fu E, Lou H, et al. IL-6 induced M1 type macrophage polarization increases radiosensitivity in HPV positive head and neck cancer. Cancer Lett. 2019;456:69\u201379.","journal-title":"Cancer Lett"},{"key":"1666_CR52","doi-asserted-by":"crossref","unstructured":"Ou D, Adam J Garberis I, et al. Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo\/bioradiotherapy. Radiother Oncol. 2019;130:89\u201396.","DOI":"10.1016\/j.radonc.2018.08.013"},{"key":"1666_CR53","doi-asserted-by":"publisher","first-page":"e0274830","DOI":"10.1371\/journal.pone.0274830","volume":"17","author":"J Hur","year":"2022","unstructured":"Hur J, Ku BM, Park S, et al. Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma. PLoS ONE. 2022;17:e0274830.","journal-title":"PLoS ONE"},{"key":"1666_CR54","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/jnci\/djab215","volume":"114","author":"G Corredor","year":"2022","unstructured":"Corredor G, Toro P, Koyuncu C, et al. An imaging biomarker of tumor-infiltrating lymphocytes to risk stratify patients with HPV-associated oropharyngeal cancer. J Natl Cancer Inst. 2022;114:609\u201317.","journal-title":"J Natl Cancer Inst"},{"key":"1666_CR55","doi-asserted-by":"publisher","first-page":"104373","DOI":"10.1016\/j.ebiom.2022.104373","volume":"86","author":"PY Zeng","year":"2022","unstructured":"Zeng PY, Cecchini MJ, Barrett JW, et al. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-drive treatment de-intensification. eBiomedicine. 2022;86:104373.","journal-title":"eBiomedicine"},{"key":"1666_CR56","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41597-023-02611-3","volume":"10","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang Q, Tao Y, et al. Characterization of immune microenvironment in patients with HPV-positive and negative head and neck cancer. Scientific Data. 2023;10:694.","journal-title":"Scientific Data"},{"key":"1666_CR57","doi-asserted-by":"publisher","first-page":"104373","DOI":"10.1016\/j.ebiom.2022.104373","volume":"86","author":"PY Zeng","year":"2022","unstructured":"Zeng PY, Cecchini MJ, Barrett JW, et al. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. EBioMedicine. 2022;86:104373.","journal-title":"EBioMedicine"},{"key":"1666_CR58","doi-asserted-by":"publisher","first-page":"1212454","DOI":"10.3389\/fonc.2023.1212454","volume":"13","author":"G Wichman","year":"2023","unstructured":"Wichman G, Vetter N, Lehmann C, et al. Outcome differences in HPV-driven head and neck squamous cell carcinoma attributable to altered human leukocyte antigen frequencies. Front Oncol. 2023;13:1212454.","journal-title":"Front Oncol"},{"key":"1666_CR59","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/cncr.30570","volume":"123","author":"M Hajek","year":"2017","unstructured":"Hajek M, Sewell A, Kaech S, et al. TRAF3\/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer. 2017;123:1778\u201390.","journal-title":"Cancer"},{"key":"1666_CR60","doi-asserted-by":"publisher","first-page":"707","DOI":"10.18632\/oncotarget.28232","volume":"13","author":"TP Schrank","year":"2022","unstructured":"Schrank TP, Prince AC, Sathe T, et al. NF-\u03baB over-activation portends improved outcomes in HPV-associated head and neck cancer. Oncotarget. 2022;13:707\u201322.","journal-title":"Oncotarget"},{"key":"1666_CR61","doi-asserted-by":"publisher","first-page":"e2216532120","DOI":"10.1073\/pnas.2216532120","volume":"120","author":"TP Schrank","year":"2023","unstructured":"Schrank TP, Kothari A, Weir WH, et al. Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors. PNAS. 2023;120:e2216532120.","journal-title":"PNAS"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01666-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T01:03:28Z","timestamp":1747271008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01666-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01666-2","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"10 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The lead author (AC) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency Statement"}}]}}